A meta-analysis to identify factors associated with CPAP machine purchasing in patients with obstructive sleep apnea

BUNDIT SAWUNYAVISUTH¹, CHETTA NGAMJARUS² and KITTISAK SAWANYAWISUTH³

¹Department of Marketing, Faculty of Business Administration and Accountancy; ²Department of Epidemiology and Biostatistics, Faculty of Public Health; ³Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand

Received January 3, 2022; Accepted February 22, 2022

DOI: 10.3892/br.2022.1528

Abstract. Obstructive sleep apnea (OSA) is a common disease and related to several cardiovascular diseases. Treatment with a continuous positive airway pressure (CPAP) machine is effective. However, not all patients with OSA purchase a CPAP machine for personal use. Previous studies showed different predictors of CPAP machine purchasing in patients with OSA. The present study aimed to summarize and identify predictors of CPAP purchasing using meta-analysis. The study was conducted using factors associated with CPAP purchasing in patients with OSA. The types of studies conducted in adult patients with OSA included: Randomized controlled trials, observational studies or descriptive studies comparing factors between those who purchased CPAP and those who did not. A total of five databases, including PubMed, Central database, Scopus, CINAHL Plus and Web of Science, were searched, and the final search was performed on February 8, 2021. Predictors for CPAP purchasing were determined. There were 598 articles from five databases, which met the inclusion criteria. After duplicated article removal, 390 articles were included in the screening process. There were 12 eligible articles for full text evaluation, and of those, eight studies met the study criteria with 1,605 patients from four countries. There were 11 variables that were available for a comparison between those who purchased the CPAP machine and those who did not, and six factors were different between the two groups: Age, years of education, income, smoking, Epworth Sleepiness Scale (ESS) score and apnea hypopnea index/respiratory disturbance index (AHI/RDI). The AHI/RDI was significantly different between the two groups, with the highest mean difference of 10.40 events/h (95% CI, 4.95-15.86). Patients who purchased

Correspondence to: Professor Kittisak Sawanyawisuth, Department of Medicine, Faculty of Medicine, Khon Kaen University, 123 Mittraphap Road, Khon Kaen 40002, Thailand E-mail: kittisak@kku.ac.th CPAP were older (1.11 years), had more years of education (0.93 years), smoked more (1.15 pack/year), and had both higher ESS (0.61) and AHI/RDI (10.40) than those who did not purchase CPAP. Additionally, those who purchased CPAP had a 1.47 times higher income than those who did not. In conclusion, specific personal customer and clinical factors were related to the decision of CPAP purchase in patients with OSA.

Introduction

Obstructive sleep apnea (OSA) is a common disease in humans. A review on population studies reported that OSA may be found in both men and women with the highest prevalence rate of 37 and 50%, respectively (1). It is also known that OSA is related to five major cardiovascular diseases, including hypertension, heart failure, atrial fibrillation, coronary artery disease and stroke (2-5). A sleep cohort study, conducted in the USA, found that untreated patients with severe sleep disordered breathing presented with coronary artery disease or heart failure 2.6 times more often compared with those without OSA (95% CI, 1.1-6.1) (6). The first line treatment for OSA is the usage of a continuous positive airway pressure (CPAP) machine, as it is cost effective with 15,915 USD per quality-adjusted life year gained (7,8).

Other than the improvement in the quality of life, CPAP therapy, for at least 4 h per night in patients with OSA, reduces the risks of acute coronary artery disease or heart attack by 83% (95% CI, 0.03-0.81) (9). Despite the benefits of CPAP therapy, not all patients with OSA purchase the machine for personal use. The CPAP purchasing rate in patients with OSA varies between 33 and 77% (10,11). There are several predictors for CPAP purchasing in patients with OSA, such as income, socioeconomic status and health insurance (9-11). A study from Mexico (12) found that patients with OSA and public health insurance had a 1.71 times higher chance of purchasing a CPAP machine compared with those without insurance (95% CI, 1.04-2.83), whereas other studies reported that predictors for CPAP purchasing were age and OSA severity (11,13). An increase in age, by one year, showed a 7% higher chance of CPAP purchasing (13). Additionally, a previous study found that marketing strategies may be valid predictors for CPAP purchasing (10). Those who purchased a

Key words: age, income, smoking, apnea hypopnea index, respiratory disturbance index

CPAP machine preferred to have the option of several CPAP models than those who did not purchase a CPAP machine (3.79 vs. 3.36/5 by Likert scale; P=0.092). As there are several and inconsistent predictors of CPAP purchasing, the present study aimed to summarize and identify predictors of CPAP purchasing using meta-analysis. Furthermore, there is a lack of meta-analyses and systematic reviews of predictors of CPAP purchasing in patients with OSA in the literature.

Materials and methods

Study design. The present meta-analysis included factors associated with the purchase of a CPAP machine in patients with OSA. The types of studies conducted in adult patients with OSA included: Randomized controlled trials, observational studies or descriptive studies comparing factors between those who purchased CPAP and those who did not. The diagnosis of OSA was made using polysomnography upon evidence of an apnea-hypopnea index (AHI) or a respiratory disturbance index (RDI) of five or more events/h. After being diagnosed with OSA, CPAP trial or CPAP titration was initiated either in a sleep laboratory or at home. CPAP titration is performed with the aim of identifying the appropriate CPAP pressure for each patient. A decision to purchase a CPAP machine is made after CPAP titration. Studies conducted in adult patients with OSA that had received CPAP titration either in a sleep laboratory or at home were included.

Literature search and data extraction. In the present meta-analysis, five databases were searched: PubMed (https://pubmed.ncbi.nlm.nih.gov), Central database (www. cochranelibrary.com/central), Scopus (www.scopus.com), CINAHL Plus (https://web.s.ebscohost.com/) and Web of Science (www.webofknowledge.com). The search terms used were 'obstructive sleep apnea', 'sleep apnea syndrome', 'predict*', 'independent', 'factor*', 'variable*', 'purchase*', 'buy', 'bought', 'pay', 'paid', 'expend*' and 'spend*', where " was used to search for all terms which began with the preceding letters. The full list of search terms is shown in Tables SI-V. The final search was performed on February 8, 2021. After the duplicates were removed, initial screening was performed for non-relevant articles. Studies were considered relevant if they had been conducted to evaluate different factors between patients who purchased a CPAP machine and those who did not. Data extraction and full text reports were reviewed by two independent authors (BS and KS). Of these, the articles that met the study criteria were included in the final analysis (14).

Studied variables and outcomes. The studied variables included both marketing and clinical factors. The definitions of the studied variables were as follows: Average to high income determined in each study, which may vary among countries; health insurance covering CPAP machine costs, which indicated cost reimbursement by the insurer; and Epworth Sleepiness Scale (ESS) score, which is a subjective sleepiness evaluation method with a value range of 0-24 (15). The primary outcome assessed were factors that varied between patients who purchased a CPAP machine and those who did not. At least two studies were required to calculate the differences of the studied variables between the two groups. The mean differences were calculated between the two groups with a 95% CI for numerical factors and the odds ratio with 95% CI for categorical outcomes. Heterogeneity was computed and reported as I squared (I²). A forest plot of each comparison was created based on I². If I² was \leq 75%, fixed effect was used. For factors displaying an I² value of >75%, the random effect was used.

Evaluation of the study quality. The Newcastle-Ottawa Scale, adapted for cross-sectional studies, was used to evaluate the study quality of observational studies (16). The scale comprised three categories: Selection process, comparability and outcome measurement, with a score of 5, 2 and 3 points, respectively. The total score was 10 points and classified as very good (9-10 points), good (7-8 points), satisfactory (5-6 points) and non-satisfactory (0-4 points). Study quality was evaluated independently by two authors (BS and CN). Disagreements between these two authors were discussed and a final decision was made by a third reviewer (KS). All analyses were performed using Review Manager 5.4 (Copenhagen, The Nordic Cochrane Centre, The Cochrane Collaboration, Denmark).

Results

Study inclusion. There were 598 articles from five databases, which met the search criteria (Fig. 1). After duplicate article removal, 390 articles were included in the screening process. There were 12 articles found to be eligible for full text evaluation. A total of four studies were excluded: Two studies were excluded as CPAP compliance was evaluated, not purchasing of CPAP machines; one study was excluded as the rate of CPAP purchasing did not include variable evaluation; and one study was excluded as only the abstract was available, which was from a conference. In total, there were eight eligible studies involving 1,605 patients from four countries (6-10,17): Five studies from Israel (11,16-20), one from Mexico (12), one from Poland (17) and one from Thailand (10). The most recent study was published in 2018 by Sawunyavisuth (10) from Thailand (Table I).

Details of the included studies. The most common study design was cross-sectional and was used in three of the studies (10,13,18). The diagnosis of OSA was made using polysomnography; however, the inclusion criteria for OSA were variable, with the highest AHI of 30 events/h (11). The duration of CPAP titration or trial, prior to CPAP purchase, was a maximum of 2 weeks (11,13,18). Not all patients with OSA, in three of the studies, underwent CPAP titration [Brin et al (18), 183/400 patients; Shahrabani et al (19), 150/194 patients; Simon-Tuval et al (13), 132/162 patients]. In these three studies, data for analysis were obtained from the total population in the study. Most studies used self-administered questionnaires or telephone interviews to record patient information. The numbers of participating patients varied between 50 (20) and 400 (18), with an average CPAP purchasing rate of 49.8%. Only one study evaluated marketing strategies on CPAP purchasing (10).

Study outcomes. There were 11 variables available for comparison between patients who purchased a CPAP

First author/s, year	Country	Study design	Diagnosis of OSA	Duration of CPAP trial	Data	Total cases, n	Purchased, n (%)	Did not purchase, n ($\%$)	(Refs.)
Torre Bouscoulet <i>et al</i> , 2007	Mexico	NA	AHI >5/h or desaturation index >15/h	NA	Telephone contact	304	169 (55.6)	135 (44.4)	(12)
Brin <i>et al</i> , 2005 ^a	Israel	Cross- sectional	RDI >20/h or RDI <20/h with FDS and FSS >9	2 weeks	Self- administered	400 183^{b}	128 (32) 128 (70) ^b	272 (68) 55 (30) ^b	(18)
Byśkiniewicz, 2006	Poland	NA	NA	NA	NA	184	116 (63)	68 (37)	(17)
Sawunyavisuth, 2018	Thailand	Cross-	Polysonno-	3 nights	Self-reported	53	41 (77.36)	12 (22.64)	(10)
Shahrabani <i>et al</i> , 2014 ^a	Israel	sectional NA	graphy NA	Varied	questionnaire Phone	194	100 (52)	94 (48)	(19)
Simon-Tuval <i>et al</i> , 2009 ^a	Israel	Cross- sectional	NA	2 weeks	interview Questionnaire	162	65 (40)	97 (60)	(13)
Tarasiuk <i>et al</i> , 2012 ^{cd}	Israel	Longitudinal interventional	AHI $>$ 30/h or $>$ 15/h with	2 weeks	Questionnaire, telephone	121 (control	40 (33.1)	81 (66.9)	(11)
			ESS >10 (moderate to severe)		survey	group) 137 (incen- tive	65 (47.4)	72 (52.6)	
Tzischinsky et al, 2011	Israel	NA	NA	NA	Questionnaire, telephone interview	group) 50	24 (48)	26 (52)	(20)

Table I. Eligible studies for meta-analysis of patients who purchased a CPAP machine and those who did not.

index; EDS, Dallce Ę nısı of two groups, control group and incentive group; "comprised of two groups. CPAP, continuous positive airway pressure; OSA, obstructive sleep apnea; RDI, respiratory excessive daytime sleepiness; ESS, Epworth Sleepiness Scale score; AHI, apnea-hypopnea index; NA, not available.




Figure 1. A flow chart showing the stages involved in searching of literature and meta-analysis on purchasing a CPAP machine in patients with obstructive sleep apnea. CPAP, continuous positive airway pressure.

	Purc	hased (CPAP	Did not p	urchase	CPAP		Mean difference		М	ean differend	ce	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV,	Fixed, 95%	CI	
Bouscoulet, 2007	51.2	13.1	169	50.6	11.4	135	9.6%	0.60 [-2.16, 3.36]				_	
Brin, 2005	54.1	10.1	128	53.7	10.8	272	15.5%	0.40 [-1.77, 2.57]				-	
Byskiniewicz, 2006	49.2	8.7	116	50.5	10.6	68	8.2%	-1.30 [-4.28, 1.68]					
Shahrabani , 2014	55.76	10.93	100	52.74	11.1	94	7.6%	3.02 [-0.08, 6.12]			+	• • •	
Simon-Tuval , 2009	58.6	10.6	65	52.4	12.3	97	5.8%	6.20 (2.65, 9.75)					
Tarasiuk control group, 2012	50.3	8.3	40	51.1	11.8	81	5.5%	-0.80 [-4.44, 2.84]			•	-	
Tarasiuk incentive group, 2012	54.4	9.9	65	47.1	10.1	72	6.5%	7.30 [3.95, 10.65]					
Tzischinsky, 2011	56.04	2.25	24	55.84	2.54	26	41.3%	0.20 [-1.13, 1.53]			-		
Total (95% CI)			707			845	100.0%	1.11 [0.26, 1.97]			•		
Heterogeneity: Chi ² = 28.36, df = 7	(P = 0.000	2); l ² = 7	5%										
Test for overall effect: Z = 2.55 (P =	0.01)								-10	-5	0	5	10
	,									Did not purchas	e CPAP Pur	chased CPAP	

Figure 2. Comparison of age between patients who purchased a CPAP machine and those who did not. CPAP, continuous positive airway pressure; df, degrees of freedom; I², percentage of variation across studies; IV, inverse variance.

machine and those who did not (Figs. 2-12). These factors were age (Fig. 2), sex (Fig. 3), years of education (Fig. 4), living with a partner (Fig. 5), income (Fig. 6), insurance (Fig. 7), smoking (Fig. 8), hypertension/cardiovascular

disease (Fig. 9), ESS (Fig. 10), body mass index (Fig. 11) and AHI/RDI (Fig. 12). A total of six factors were found to be significantly different between both groups: Age (Fig. 2), years of education (Fig. 4), income (Fig. 6), smoking (Fig. 8),

	Purchased	CPAP	Did not purchase	CPAP		Odds ratio	Odds ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% Cl
Bouscoulet, 2007	118	169	88	135	26.6%	1.24 [0.76, 2.00]	
Brin, 2005	102	123	223	269	21.5%	1.00 [0.57, 1.77]	
Sawunyavisuth, 2018	27	41	6	12	2.9%	1.93 [0.52, 7.10]	
Shahrabani, 2014	76	100	76	94	16.9%	0.75 [0.38, 1.49]	
Simon-Tuval , 2009	52	65	67	97	9.7%	1.79 [0.85, 3.77]	+
Tarasiuk control group, 2012	36	40	60	81	3.6%	3.15 [1.00, 9.91]	
Tarasiuk incentive group, 2012	50	65	58	72	11.4%	0.80 [0.35, 1.83]	
Tzischinsky, 2011	11	24	16	26	7.5%	0.53 [0.17, 1.63]	
Total (95% CI)		627		786	100.0%	1.14 [0.89, 1.47]	•
Total events	472		594				
Heterogeneity: Chi2=9.27, df=7 (f	P=0.23); I ² =2	4%					0.01 0.1 1 10 100
Test for overall effect: Z=1.03 (P=	= 0.30)						Did not purchase CPAP Purchased CPAP

Figure 3. Comparison of male sex between patients who purchased a CPAP machine and those who did not. CPAP, continuous positive airway pressure; df, degrees of freedom; I², percentage of variation across studies; M-H, Mantel-Haenszel.

	Purcha	ased C	PAP	Did not pu	irchase	CPAP		Mean difference	Mean difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Bouscoulet, 2007	9.2	5.6	169	8.5	5.7	135	43.4%	0.70 (-0.58, 1.98)	
Simon-Tuval , 2009	13.4	3.4	65	12.3	3.8	97	56.6%	1.10 [-0.02, 2.22]	
Total (95% CI)			234			232	100.0%	0.93 [0.08, 1.77]	-
Heterogeneity: Chi² = 0 Test for overall effect: Z			4); I² = 0%						-4 -2 0 2 4 Did not purchase CPAP Purchased CPAP

Figure 4. Comparison of years of education between patients who purchased a CPAP machine and those who did not. CPAP, continuous positive airway pressure; df, degrees of freedom; I², percentage of variation across studies; IV, inverse variance

	Purchased	CPAP	Did not purchase	CPAP		Odds ratio	Odds ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI
Simon-Tuval, 2009	39	64	75	95	67.4%	0.42 [0.21, 0.84]	
Tarasiuk control group, 2012	37	40	68	81	9.6%	2.36 [0.63, 8.81]	
Tarasiuk incentive group, 2012	56	65	61	72	22.9%	1.12 [0.43, 2.91]	
Total (95% CI)		169		248	100.0%	0.77 [0.47, 1.26]	-
Total events	132		204				
Heterogeneity: Chi2= 6.30, df=2	(P=0.04); I ² =	68%					
Test for overall effect: Z=1.06 (P	=0.29)						Did not purchase CPAP Purchased CPAP

Figure 5. Comparison of living with partner between patients who purchased a CPAP machine and those who did not. CPAP, continuous positive airway pressure; df, degrees of freedom; I², percentage of variation across studies; M-H, Mantel-Haenszel.

	Purchased	CPAP	Did not purchase	CPAP		Odds ratio	Odds ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Sawunyavisuth, 2018	32	41	6	12	3.5%	3.56 [0.92, 13.74]	2
Shahrabani, 2014	78	100	58	94	22.9%	2.20 [1.17, 4.13]	
Simon-Tuval, 2009	20	65	21	97	20.3%	1.61 [0.79, 3.29]	
Tarasiuk control group, 2012	28	40	44	81	15.2%	1.96 [0.88, 4.39]	
Tarasiuk incentive group, 2012	30	65	43	72	38.2%	0.58 [0.29, 1.14]	
Total (95% CI)		311		356	100.0%	1.47 [1.06, 2.05]	•
Total events	188		172				
Heterogeneity: Chi ² =11.05, df=4	(P=0.03); I ² =	64%					0.01 0.1 1 10 100
Test for overall effect: Z=2.29 (P	= 0.02)						Did not purchase CPAP Purchased CPAP

Figure 6. Comparison of average to high income between patients who purchased a CPAP machine and those who did not. CPAP, continuous positive airway pressure; df, degrees of freedom; I², percentage of variation across studies; M-H, Mantel-Haenszel.

ESS (Fig. 10) and AHI/RDI (Fig. 12). AHI/RDI was significantly different between the two groups with the highest mean difference of 10.40 events/h (95% CI, 4.95-15.86) as shown in Fig. 12. Patients who purchased a CPAP machine were older (by 1.11 years), had more years of education (0.93 years more), were smoking more (by 1.15 pack/year), and had higher ESS (by 0.61) and AHI/RDI (by 10.40) scores than those who did not purchase a CPAP machine, as shown in Figs. 2, 4, 8, 10 and 12, respectively. Additionally, those who purchased a CPAP machine had a 1.47 times higher income than those who did not (Fig. 6). The quality of most of the studies was evaluated as satisfactory, except for the longitudinal study by Tarasiuk *et al* (11), which was considered as good, with a score of 7/10 (Table II). Furthermore,

	Purchased	CPAP	Did not purchase	CPAP		Odds ratio	Odds ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% CI
Bouscoulet, 2007	70	169	45	135	93.5%	1.41 [0.88, 2.26]	-+
Sawunyavisuth, 2018	32	41	6	12	6.5%	3.56 [0.92, 13.74]	
Total (95% CI)		210		147	100.0%	1.55 [1.00, 2.42]	◆
Total events	102		51				
Heterogeneity: Chi ² =1.5	9, df=1 (P=0.	21); I ² =3	7%				0.01 0.1 1 10 100
Test for overall effect: Z	=1.94 (P=0.05	5)					Did not purchase CPAP Purchased CPAP

Figure 7. Comparison of having health insurance cover between patients who purchased a CPAP machine and those who did not. CPAP, continuous positive airway pressure; df, degrees of freedom; 1², percentage of variation across studies; M-H, Mantel-Haenszel.




Figure 8. Comparison of smoking (pack/year) between patients who purchased a CPAP machine and those who did not. CPAP, continuous positive airway pressure; df, degrees of freedom; I², percentage of variation across studies; IV, inverse variance.




Figure 9. Comparison of having hypertension/cardiovascular disease between patients who purchased a CPAP machine and those who did not. CPAP, continuous positive airway pressure; df, degrees of freedom; I^2 , percentage of variation across studies; M-H, Mantel-Haenszel.




Figure 10. Comparison of Epworth Sleepiness Scale score between patients who purchased a CPAP machine and those who did not. CPAP, continuous positive airway pressure; df, degrees of freedom; I², percentage of variation across studies; IV, inverse variance.

the study by Byśkiniewicz (17) was not scored as it was published in Polish.

Discussion

The six significant factors that were compared between patients with OSA who did or did not purchase a CPAP machine can be categorized into two groups: Customer-related and clinical factors. The personal customer factors included age, years of education and income, while the clinical factors were age, smoking, ESS and AHI/RDI. In addition, age was included in both groups as it can be classified as both a personal customer factor and clinical factor.

There are several customer behavior models, such as the Nicosia model, Howard Sheth model, or Engel, Blackwell and Minard model (21,22). The significant factors in the present study are personal customer factors, which is one factor of several customer behaviors in the black box consumer behavior model (23). Additionally, a previous study from China found that these personal factors are related to higher chances of purchasing healthcare devices; however, the purchase of a

First author/s, year	Study design	Selection process (5)	Comparability (2)	Outcome measures (3)	Total (10)	Interpretation	(Refs.)
Torre Bouscoulet <i>et al</i> , 2007	NA	3	1	1	5	Satisfactory	(12)
Brin et al, 2005	Cross-sectional	3	1	1	5	Satisfactory	(18)
Byśkiniewicz, 2006	NA	NA	NA	NA	NA	NA due to non- English article	(17)
Sawunyavisuth, 2018	Cross-sectional	3	1	2	6	Satisfactory	(10)
Shahrabani et al, 2014	NA	3	1	2	6	Satisfactory	(19)
Simon-Tuval <i>et al</i> , 2009	Cross-sectional	3	1	2	6	Satisfactory	(13)
Tarasiuk et al, 2012	Longitudinal	4	1	2	7	Good	(11)
Tzischinsky <i>et al</i> , 2011	NA	3	1	2	6	Satisfactory	(20)

Table II. Study quality evaluation using the Newcastle-Ottawa Scale adapted for cross-sectional studies of the included studies.

NA, not applicable.

	Purc	hased	CPAP	Did not	purchas	e CPAP		Mean difference		Mean di	ference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% C	I	IV, Randon	n, 95% CI	
Bouscoulet, 2007	36.7	7.4	169	35.8	6.2	135	12.6%	0.90 [-0.63, 2.43]		-	•	
Brin, 2005	32.4	5.5	128	33.1	6.8	272	12.9%	-0.70 [-1.95, 0.55]			-	
Byskiniewicz, 2006	35	6.3	116	31.1	6.3	62	12.1%	3.90 [1.96, 5.84]				
Shahrabani , 2014	31.63	4.96	100	31.47	6.27	94	12.5%	0.16 [-1.44, 1.76]				
Simon-Tuval , 2009	32.6	4.8	65	32.1	5.7	97	12.5%	0.50 [-1.13, 2.13]				
Tarasiuk control group, 2012	32.5	4.8	40	37.3	6.5	81	12.0%	-4.80 [-6.85, -2.75]				
Tarasiuk incentive group, 2012	33.5	5.4	65	31.2	5.3	72	12.3%	2.30 [0.50, 4.10]				
Tzischinsky, 2011	35	1.71	24	30.2	1.16	26	13.2%	4.80 [3.98, 5.62]				
Total (95% CI)			707			839	100.0%	0.92 [-1.21, 3.05]				
Heterogeneity: Tau ² = 8.75; Chi ² =	119.28, df=	= 7 (P <	0.00001)	; I² = 94%					H-	<u> </u>	<u>!</u>	- 10
Test for overall effect: Z = 0.85 (P =	0.40)								-10	-5 0	5	10
										Did not purchase CPAP	Purchased CPAP	

Figure 11. Comparison of body mass index (kg/m²) between patients who purchased a CPAP machine and those who did not. CPAP, continuous positive airway pressure; df, degrees of freedom; I², percentage of variation across studies; IV, inverse variance.

	Purch	ased Cl	PAP	Did not	purchase	CPAP		Mean difference	Mean difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% C	I IV, Random, 95% CI
Bouscoulet, 2007	61	35.5	169	47.4	32.1	135	11.6%	13.60 [5.99, 21.21]	
Brin, 2005	40.1	24	128	36.3	22.8	272	13.3%	3.80 [-1.16, 8.76]	+
Byskiniewicz, 2006	54.6	21	116	41.7	19.9	62	12.5%	12.90 [6.64, 19.16]	-
Shahrabani, 2014	40.77	21.54	100	34.75	18.4	94	12.9%	6.02 [0.39, 11.65]	+
Simon-Tuval, 2009	48.8	23.2	65	35.5	23.8	97	11.8%	13.30 [5.94, 20.66]	
Tarasiuk control group, 2012	45.3	23.4	40	37.3	20.1	81	11.0%	8.00 [-0.47, 16.47]	
Tarasiuk incentive group, 2012	41.5	19.1	65	36.1	20.5	72	12.3%	5.40 [-1.23, 12.03]	
Tzischinsky, 2011	40.83	4.19	24	21.58	2.52	26	14.7%	19.25 [17.31, 21.19]	•
Total (95% CI)			707			839	100.0%	10.40 [4.95, 15.86]	•
Heterogeneity: Tau ² =51.70;Chi ² Test for overall effect: Z=3.74 (P		•	0.00001); I²=88%					-100 -50 0 50 100 Did not purchase CPAP Purchased CPAP

Figure 12. Comparison of apnea-hypopnea index or respiratory disturbance index between patients who purchased a CPAP machine and those who did not. CPAP, continuous positive airway pressure; df, degrees of freedom; I², percentage of variation across studies; IV, inverse variance.

CPAP machine was not included in the study (24). Patients with OSA who purchased a CPAP machine were 1.11 years older, had 0.93 years longer education and, on average, a 1.47 times higher income than those who did not purchase a CPAP machine. The previous Chinese study found that older age, higher education (Junior college degree) and higher income had odds ratios of 6.65, 4.02 and 7.88, respectively (24). Both studies identified similar trends for these predictors, but different magnitudes as this study was more specific to the use of CPAP machines by summation of several studies. Furthermore, differences in defining what constitutes high income among countries and currency differences require a cautious interpretation of CPAP purchase. Of note, the present meta-analysis indicated that patients with OSA and health insurance coverage had a 1.55 times higher chance of purchasing a CPAP machine than those without such coverage (95% CI, 1.00-2.42), as shown in Fig. 7. It should be noted that insurance almost reached statistical significance in the present study. The aforementioned coverage reduces the machine's cost, making it more affordable.

The four clinical factors, which were found to change significantly between the two groups, were related to severity of OSA. Older age, smoking and daytime sleepiness are indicators of severe OSA (25-27). Older age has been reported to be related to increased severity of OSA, with a correlation coefficient of 0.331 (P<0.01) (25), whereas smoking was associated with moderate/severe OSA by 4.4 times (95% CI, 1.5-13) (26). A high ESS score of >10 was found more often in severe OSA, as compared with mild or moderate OSA (40.2 vs. 26.7 and 29.6%, respectively; P<0.001) (27). As a result, more patients with more severe OSA tended to purchase a CPAP machine more often than those with less severe OSA. In the present study, patients with OSA who purchased a CPAP machine had a higher AHI by 10.40 events/h than those who did not purchase a CPAP machine (Fig. 12). Of note, this AHI/RDI mean difference displayed the highest value among the studied variables. As previously reported, patients with severe OSA had higher chances of sudden death or developing cardiovascular diseases, including coronary artery heart disease, heart failure, left ventricular hypertrophy, hypertension or atrial fibrillation (28-30). Those patients with OSA with an AHI score of >20 events/h are likely to have sudden cardiac death (29). Therefore, patients with severe OSA may have several cardiovascular diseases, as well as being more symptomatic, leading to higher chances of purchasing a CPAP machine.

There are some limitations in the present study. First, most studies conducted in Israel may have different cultures or purchasing habits from other countries. Second, some patients did not undergo a CPAP trial prior to CPAP purchase (8-10). In addition, the duration of a CPAP titration prior to a decision of purchasing a CPAP machine varied (Table I). Third, some studied variables, such as body mass index and AHI, bore high heterogeneity. Fourth, CPAP compliance or other related conditions of OSA such as CPAP intervention, exercise intervention, cognitive function, or asthma were not studied (31-38). Finally, marketing strategies which may be related to CPAP purchase were investigated in only one study (10). Therefore, further studies regarding the roles of marketing strategies in CPAP purchase may be required.

In conclusion, personal customer factors and clinical factors were related to the decision of patients with OSA to purchase a CPAP device.

Acknowledgements

Not applicable.

Funding

The present study was funded by the Research and International Affair, Faculty of Medicine (grant no. SY65101), Khon Kaen University, Khon Kaen, Thailand.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

BS designed the study, extracted the data, evaluated study quality, performed the statistical analysis, interpreted data, and wrote the manuscript. CN performed the searches, evaluated study quality, performed the statistical analysis, interpreted the data, and reviewed the manuscript. KS evaluated study quality, performed the statistical analysis, interpreted the data, and reviewed the manuscript. BS and KS confirm the authenticity of all the raw data. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

- 1. Franklin KA and Lindberg E: Obstructive sleep apnea is a common disorder in the population-a review on the epidemiology of sleep apnea. J Thorac Dis 7: 1311-1322, 2015.
- 2. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corrà U, Cosyns B, Deaton C, et al: 2016 European guidelines on cardiovascular disease prevention in clinical practice: The sixth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European association for cardiovascular prevention & rehabilitation (EACPR). Eur Heart J 37: 2315-2381, 2016.
- 3. Khamsai S, Chootrakool A, Limpawattana P, Chindaprasirt J, Sukeepaisarnjaroen W, Chotmongkol V, Silaruks S, Senthong V, Sittichanbuncha Y, Sawunyavisuth B and Sawanyawisuth K: Hypertensive crisis in patients with obstructive sleep apnea-induced hypertension. BMC Cardiovasc Disord 21: 310, 2021.
- 4. Khamsai S, Mahawarakorn P, Limpawattana P, Chindaprasirt J, Sukeepaisarnjaroen W, Silaruks S, Senthong V, Sawunyavisuth B and Sawanyawisuth K: Prevalence and factors correlated with hypertension secondary from obstructive sleep apnea. Multidiscip Respir Med 16: 777, 2021.
- Khamsai S, Kachenchart S, Sawunyavisuth B, Limpawattana P, Chindaprasirt J, Senthong V, Chotmongkol V, Pongkulkiat P and Sawanyawisuth K: Prevalence and risk factors of obstructive sleep apnea in hypertensive emergency. J Emerg Trauma Shock 14: 104-107, 2021.
- Hla KM, Young T, Hagen EW, Stein JH, Finn LA, Nieto FJ and Peppard PE: Coronary heart disease incidence in sleep disordered breathing: The Wisconsin sleep cohort study. Sleep 38: 677-684, 2015.
- Pietzsch JB, Garner A, Cipriano LE and Linehan JH: An integrated health-economic analysis of diagnostic and therapeutic strategies in the treatment of moderate-to-severe obstructive sleep apnea. Sleep 34: 695-709, 2011.
- Tietjens JR, Claman D, Kezirian EJ, De Marco T, Mirzayan A, Sadroonri B, Goldberg AN, Long C, Gerstenfeld EP and Yeghiazarians Y: Obstructive sleep apnea in cardiovascular disease: A review of the literature and proposed multidisciplinary clinical management strategy. J Am Heart Assoc 8: e010440, 2019.

- Peker Y, Thunström E, Glantz H and Eulenburg C: Effect of obstructive sleep apnea and CPAP treatment on cardiovascular outcomes in acute coronary syndrome in the RICCADSA trial. J Clin Med 9: 4051, 2020.
- Sawunyavisuth B: What are predictors for a continuous positive airway pressure machine purchasing in obstructive sleep apnea patients? Asia Pac J Sci Technol 23: APST-23-03-10, 2018.
 Tarasiuk A, Reznor G, Greenberg-Dotan S and Reuveni H:
- Tarasiuk A, Reznor G, Greenberg-Dotan S and Reuveni H: Financial incentive increases CPAP acceptance in patients from low socioeconomic background. PLoS One 7: e33178, 2012.
- 12. Torre Bouscoulet L, López Escárcega E, Castorena Maldonado A, Vázquez García JC, Meza Vargas MS and Pérez-Padilla R: Continuous positive airway pressure used by adults with obstructive sleep apneas after prescription in a public referral hospital in Mexico City. Arch Bronconeumol 43: 16-21, 2007 (In Spanish).
- Simon-Tuval T, Reuveni H, Greenberg-Dotan S, Oksenberg A, Tal A and Tarasiuk A: Low socioeconomic status is a risk factor for CPAP acceptance among adult OSAS patients requiring treatment. Sleep 32: 545-552, 2009.
- Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP and Thomas J: Updated guidance for trusted systematic reviews: A new edition of the cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev 10: ED000142, 2019.
- 15. Johns MW: A new method for measuring daytime sleepiness: The Epworth sleepiness scale. Sleep 14: 540-545, 1991.
- Sisay M, Mengistu G and Edessa D: Epidemiology of selfmedication in Ethiopia: A systematic review and meta-analysis of observational studies. BMC Pharmacol Toxicol 19: 56, 2018.
- Byśkiniewicz K: Factors determining the decision to initiate nCPAP therapy in patients with obstructive sleep apnea (OSA). Pneumonol Alergol Pol 74: 45-50, 2006 (In Polish).
- Brin YS, Reuveni H, Greenberg S, Tal A and Tarasiuk A: Determinants affecting initiation of continuous positive airway pressure treatment. Isr Med Assoc J 7: 13-18, 2005.
- 19. Shahrabani S, Tzischinsky O, Givati G and Dagan Y: Factors affecting the intention and decision to be treated for obstructive sleep apnea disorder. Sleep Breath 18: 857-868, 2014.
- 20. Tzischinsky O, Shahrabani S and Peled R: Factors affecting the decision to be treated with continuous positive airway pressure for obstructive sleep apnea syndrome. Isr Med Assoc J 13: 413-419, 2011.
- Goodhope O and Pcon A: Major classic consumer buying behaviour models: Implications for marketing decision-making. J Econ Sustain Dev 4: 164-172, 2013.
- 22. Waykole NH and Bhangale AI: A study of influence of digital marketing on buying behaviour of mobile phone consumers. J Inf Comput Sci 10: 411-429, 2020.
- 23. Schlesinger M, Kanouse DE, Martino SC, Shaller D and Rybowski L: Complexity, public reporting, and choice of doctors: A look inside the blackest box of consumer behavior. Med Care Res Rev 71 (Suppl 5): 38S-64S, 2014.
- 24. Wang D, Liu S, Wu J and Lin Q: Purchase and use of home healthcare devices for the elderly: A pilot study in Shanghai, China. BMC Public Health 20: 615, 2020.
- 25. Hongyo K, Ito N, Yamamoto K, Yasunobe Y, Takeda M, Oguro R, Takami Y, Takeya Y, Sugimoto K and Rakugi H: Factors associated with the severity of obstructive sleep apnea in older adults. Geriatr Gerontol Int 17: 614-621, 2017.

- 26. Krishnan V, Dixon-Williams S and Thornton JD: Where there is smoke...there is sleep apnea: Exploring the relationship between smoking and sleep apnea. Chest 146: 1673-1680, 2014.
- Kapur VK, Baldwin CM, Resnick HE, Gottlieb DJ and Nieto FJ: Sleepiness in patients with moderate to severe sleep-disordered breathing. Sleep 28: 472-477, 2005.
- 28. Soontornrungsun B, Khamsai S, Sawunyavisuth B, Limpawattana P, Chindaprasirt J, Senthong V, Chotmongkol V and Sawanyawisuth K: Obstructive sleep apnea in patients with diabetes less than 40 years of age. Diabetes Metab Syndr 14: 1859-1863, 2020.
- 29. Gami AS, Olson EJ, Shen WK, Wright RS, Ballman KV, Hodge DO, Herges RM, Howard DE and Somers VK: Obstructive sleep apnea and the risk of sudden cardiac death: A longitudinal study of 10,701 adults. J Am Coll Cardiol 62: 610-616, 2013.
- 30. Sanlung T, Sawanyawisuth K, Silaruks S, Khamsai S, Limpawattana P, Chindaprasirt J, Senthong V, Kongbunkiat K, Timinkul A, Phitsanuwong C, Sawunyavisuth B and Chattakul P: Clinical characteristics and complications of obstructive sleep apnea in srinagarind hospital. J Med Assoc Thai 103: 36, 2020.
- 31. Sawunyavisuth B: What personal experiences of CPAP use affect CPAP adherence and duration of CPAP use in OSA patients? J Med Assoc Thai 101: S245-S249, 2018.
- 32. Kaewkes C, Sawanyawisuth K and Sawunyavisuth B: Are symptoms of obstructive sleep apnoea related to good continuous positive airway pressure compliance? ERJ Open Res 6: 00169-2019, 2020.
- 33. Jeerasuwannakul B, Sawunyavisuth B, Khamsai S and Sawanyawisuth K: Prevalence and risk factors of proteinuria in patients with type 2 diabetes mellitus. Asia Pac J Sci Technol 26: APST-26-04-02, 2021.
- 34. Leethong-in M, Piyawattanapong S, Sommongkol S, Thiengtham S, Subindee S, Komniyom N, Chotchaisthit P and Chuen-arom C: The impact of a brain exercise program on cognitive functions among rural thai older adults: A quasi-experimental study. Asia Pac J Sci Technol 26: APST-26-02-08, 2021.
- 35. Sangjumrus N, Chaiear N, Saikaew K, So-ngern A and Burge PS: Developing a web application to provide information on common work-related asthma causative agents. Asia Pac J Sci Technol 26: APST-26-04-13, 2021.
- 36. Sawunyavisuth B, Ngamjarus C and Sawanyawisuth K: Any effective intervention to improve CPAP adherence in children with obstructive sleep apnea: A systematic review. Glob Pediatr Health 8: 2333794X211019884, 2021.
- Hlaing SS, Puntumetakul R, Wanpen S and Saiklang P: Updates on core stabilization exercise and strengthening exercise: A review article. Asia Pac J Sci Technol 26: APST-26-04-12, 2021.
- Manasirisuk P, Chainirun N, Tiamkao S, Lertsinudom S, Phunikhom K, Sawunyavisuth B and Sawanyawisuth K: Efficacy of generic atorvastatin in a real-world setting. Clin Pharmacol 13: 45-51, 2021.

6	0	٩	ً	T
\sim	ΒY	NC	ND	P
				I

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.